{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:57:26Z","timestamp":1766509046492,"version":"3.48.0"},"reference-count":5,"publisher":"American Medical Association (AMA)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,12,23]]},"DOI":"10.1001\/jama.2025.18237","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T16:31:04Z","timestamp":1763397064000},"page":"2233","source":"Crossref","is-referenced-by-count":0,"title":["Outcomes of Nononcology Accelerated Approvals"],"prefix":"10.1001","volume":"334","author":[{"given":"Bridget","family":"Doherty","sequence":"first","affiliation":[{"name":"Access and Policy Research, Johnson & Johnson Innovative Medicine, Titusville, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ginny","family":"Beakes-Read","sequence":"additional","affiliation":[{"name":"Global Regulatory Policy and Intelligence, Johnson & Johnson Innovative Medicine, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Friend","sequence":"additional","affiliation":[{"name":"US and Latin America, Regulatory Policy and Intelligence, Johnson & Johnson Innovative Medicine, Raritan, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"key":"jle250149r1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.10726","article-title":"Regulatory and clinical outcomes of nononcology accelerated approvals.","author":"Liu","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"jle250149r4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.6004\/jnccn.2024.7010","article-title":"Life years gained from the FDA accelerated approval program in oncology: a portfolio model.","volume":"22","author":"Benedict","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"jle250149r5","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s43441-022-00430-z","article-title":"Analysis of FDA\u2019s accelerated approval program performance December 1992\u2013December 2021.","volume":"56","author":"Beakes-Read","year":"2022","journal-title":"Ther Innov Regul Sci"},{"key":"jle250149r2","unstructured":"US Food and Drug Administration. Expedited program for serious conditions\u2014accelerated approval of drugs and biologics. Published December 2024. Accessed September 25, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/accelerated-approval-expedited-program-serious-conditions"},{"key":"jle250149r3","unstructured":"US Food and Drug Administration. Surrogate endpoint resources for drug and biologic development. Published July 2018. Accessed August 3, 2025. https:\/\/www.fda.gov\/drugs\/development-resources\/surrogate-endpoint-resources-drug-and-biologic-development"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2841555\/jama_doherty_2025_le_250149_1766440858.26176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:00:50Z","timestamp":1766505650000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2841555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":5,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.18237","relation":{},"ISSN":["0098-7484"],"issn-type":[{"type":"print","value":"0098-7484"}],"subject":[],"published":{"date-parts":[[2025,12,23]]}}}